Welcome to our dedicated page for Faeth Therapeutics SEC filings (Ticker: FTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Faeth Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Faeth Therapeutics's regulatory disclosures and financial reporting.
Faeth Therapeutics: S2G Investments, LLC reports beneficial ownership of 2,575,401 shares of common stock, equal to 9.99% of the class as of June 15, 2026. The filing states these shares reflect conversion on June 15, 2026 of Series B Non‑Voting Convertible Preferred Stock, each convertible into 1,000 common shares, and that 25,778,754 shares outstanding is the denominator used for the percentage. The filer also holds 344.271 shares of Series B Preferred (approximately 344,271 common shares on an as‑converted basis) that are not deemed beneficially owned due to a Beneficial Ownership Limitation the reporting person elected at 9.99%.